Business
Patent Statement
Patent Statement.
About this update from Proteome Sciences Plc
[{"type":"text","content":"\n \nRNS Number : 0719I Proteome Sciences PLC 28 June 2013 \n \n\nProteome Sciences plc\n \nPatent Statement\n \n28 June 2013 \n \nThe Company has again been made aware of certain speculative and inappropriate comments regarding its US biomarker patent portfolio in the light of recent US court rulings on patent eligibility, in particular the court's recent ruling against Myriad that patents will not be allowed on genes. This has no bearing on Proteome Sciences' intellectual property. Shareholders will be pleased to know that the Company received subsequent notification this week from the US Patent and Trademark Office of the allowance of a new patent in Huntington's disease. The Directors conclude that these decisions do not change the status of the Company's issued and pending US applications or impact its granted US patents which continue to remain in good standing.\n \n \nEnds\n \nFor further information please contact:\n \n\n\n\n\nProteome Sciences plc\n\n\n\n\n\n\n\nChristopher Pearce, Chief Executive Officer\n\n\nTel: +44 (0)1932 865065\n\n\n\n\nDr. Ian Pike, Chief Operating Officer\nJames Malthouse, Finance Director\n\n\n\n\n\n\n\n\n\n\n\n\nNominated Adviser\n\n\n\n\n\n\n\nCenkos Securities plc\n\n\n\n\n\n\n\nStephen Keys/Camilla Hume\n\n\nTel: +44 (0)20 7397 8900\n\n\n\n\n\n\n\n\n\n\n\n\nPublic Relations\n\n\n\n\n\n\n\nFTI Consulting\n\n\nIKON Associates \n\n\n\n\nBen Atwell / Simon Conway / Mo Noonan\n\n\nAdrian Shaw \n\n\n\n\nTel: +44 (0)20 7269 7116\n\n\nTel: +44 (0)1483 271291\n\n\n\n\n \n \nNotes to Editors:\n \nAbout Proteome Sciences\n \nProteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. Its PS Biomarker Services™ uses isobaric and isotopic Tandem Mass Tag® (TMT®) workflows developed on the latest Orbitrap® Velos and TSQ Vantage mass spectrometers to deliver rapid, robust and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt, Germany. By combining Selected Reaction Monitoring (SRM) and TMT® workflows highly multiplexed assays can be developed rapidly a...